Background {#Sec1}
==========

After more than two decades of clinical research, accelerated partial breast irradiation (APBI) is considered as an efficient and safe adjuvant treatment for low-risk breast cancer \[[@CR1], [@CR2]\]. American Society of Radiation Oncology (ASTRO) and Groupe Européen de Curiethérapie of the European Society for Radiotherapy and Oncology (GEC-ESTRO) now consider that, in a well selected population, described as "suitable" (ASTRO) and "low-risk" (ESTRO), adjuvant APBI can be proposed as an alternative to standard or slightly hypofractionnated adjuvant schedule (4 to 6 treatment weeks) \[[@CR3], [@CR4]\].

A single fraction of adjuvant APBI using multicatheter interstitial brachytherapy (MIB) permits the maximal reduction of transportations and alleviates the treatment related constraints mainly for elderly patients with frequent comorbidities \[[@CR5]\]. The single fraction schedule was challenged in retrospective and prospective studies and remained encouraging outcomes \[[@CR6]--[@CR9]\]. We already reported the early clinical outcome of a cohort of elderly women treated by a post-operative single fraction of very APBI (vAPBI) but a longer follow-up was needed to assess consistent results \[[@CR9]\].

The aim of this short report was to update the clinical outcome after vAPBI in our previously published cohort of elderly patients presenting low-risk breast cancer.

Material and methods {#Sec2}
====================

All material and methods sections were previously described in details \[[@CR9]\].

Patient selection {#Sec3}
-----------------

This is a single institution retrospective study including elderly patients presenting with low-risk breast cancer who underwent lumpectomy plus axillary evaluation followed by a single fraction of high-dose rate (HDR) MIB APBI. The patient cohort combined women enrolled in a prospective phase I/II trial (SiFEBI; [Clinical.gov](http://clinical.gov) \#NCT01727011, \[[@CR7]\]) and elderly frail patients treated before the SiFEBI trial opening. Briefly, inclusion criteria were as follow: elderly women 65 years and older, histologically proven breast carcinoma with free surgical margins, negative axillary evaluation. Patients were excluded in case of: sarcoma or lymphoma histology or with metastatic dissemination.

Treatments {#Sec4}
----------

### Breast surgery {#Sec5}

Patients underwent lumpectomy with axillary management (sentinel lymph node or axillary dissection). Four to five clips were clamped by the surgeon to mark the tumor bed before closing the lumpectomy cavity \[[@CR10]\].

### Brachytherapy {#Sec6}

Brachytherapy was performed according to the GEC-ESTRO Breast Cancer Working Group recommendations for MIB APBI \[[@CR11]\]. A post-implant CT scan was performed in order to delineate the clinical target volume (CTV) based on clips, surgical cavity and pathological margins including a total safety margin of about 2 cm \[[@CR12]\]. A single fraction of 16 Gy was prescribed to the 100% isodose. Dose constraints were as follow: D90% ≥ 105% of the prescribed dose, D100% ≥ 75%, V100 \> 95% of the CTV, V150 ≤ 40%, V200 ≤ 15%; dose non-homogeneity ratio (DNR) ≤ 35% \[[@CR7]\].

### Systemic therapy {#Sec7}

Systemic therapies such as adjuvant chemotherapy and/or hormonal treatments were dispensed according to the protocols used in the Antoine Lacassagne Cancer Center.

Follow up {#Sec8}
---------

The radiation oncologist performed iterative monthly post-brachytherapy clinics during 3 months (acute brachytherapy side effects). Then, clinical surveillance was performed twice a year, alternatively with the surgeon, with a yearly mammogram. Late toxicities were evaluated by Common Terminology Criteria for Adverse Event v4 (CTCAE.V4.0). Cosmetic evaluation was performed according to Harvard criteria \[[@CR13]\].

Statistical analysis {#Sec9}
--------------------

Description of the study population and of the different investigated parameters was made using absolute and relative frequencies for the qualitative data and summarized using descriptive statistics such as median, extreme for quantitative data. Survival time was defined between the surgery date and the event date. Local relapse free-survival (LRFS), regional relapse free-survival (RRFS), specific (SS) and overall survivals (OS) were estimated using the Kaplan-Meier method. Patients still alive were censored at the date of last follow-up. Median follow-up with 95% confidence intervals was calculated by reverse Kaplan--Meier method. Data entry and data management were performed on Ennov clinical® system and were analyzed using R 3.2.2 for Windows®.

Results {#Sec10}
=======

Patient and tumor characteristics {#Sec11}
---------------------------------

Between January 2012 and August 2015, a total of 51 lesions from 48 patients (pts) were treated with a vAPBI. Patient, tumor and treatment features are reported in Table [1](#Tab1){ref-type="table"}. Patient median age was 77.7 years \[range: 65--92\]. Most of patients were Performans Status (PS) 0 (85%). The most frequent location was the upper external quadrant (39.2%). Histological type was mainly invasive ductal carcinoma (86.2%). The median tumor size was 12 mm \[range: 3--32\] while, 4 pts. presented with a microscopic node involvement (Nmic) and 1 pt. was classified N1. The median surgical margin was 5 mm \[range: 1--10\]. One lesion was associated with peri-neural invasion. All the tumors but three had positive hormonal receptor status while Her-2 status was over-expressed in 5 pts (9.8%). Table 1Patient, lesion and treatment characteristicsPatient featuresNumber of patients%/(min -- max)Median age (years)77.765.2--92.3Performans Status 04185.5 1714.5Tumor side Left2854.9 Right2345.1Median tumor size (mm)123--32Tumor stage T1a2854.9 T1b1835.3 T1c59.8Axillary lymph node status N04690.1 N1mic47.9 N112.0Histology type Invasive ductal carcinoma4486.3 Invasive lobular carcinoma35.9 Other47.8Histological grade 13262.7 21427.4 359.8Hormonal status Positive4894.1 Negative35.9Her-2 status Over-expressed59.8 Non-over-expressed4690.2Peri-neural invasion Yes11.9 No5098.1Median Ki-67 (%)Median surg. Marg.(mm)1055--601--10Implant procedure Intra operative4792.2 Post-operative47.8Median time interv. Surg./APBI (d)71--63Median number of lines115--15Median number of planes21--3Median CTV (cc)4411--124Median V100% (%)9686--100Median V150% (%)3423--48Median V200% (%)128--21MedianDNR0.350.23--0.56*Median time interv. Surg./APBI* Median time between intervention and APBI Median surg. *marg.* median surgical margins, *DNR* Dose non-homogeneity ratio: V100/V150

Treatment characteristics {#Sec12}
-------------------------

The median time interval between surgery and vAPBI was 7 days \[range: 1--63\]. A median number of 11 vectors \[range: 5--15\] on 2 planes \[range: 1--3\] were implanted, mainly intra-operatively (92.2%). The median CTV was 44 cc \[range: 11--124\]. The median V100% was 96% \[range: 86--100\] (Table [1](#Tab1){ref-type="table"}).

Oncological outcome {#Sec13}
-------------------

With a median follow--up of 64 months \[range: 56--71\], no local relapse occurred while 1 pt. developed an axillary relapse (2.1%). Five-year LRFS, and SS were 100% and 5-year OS was 87.3% \[78.3--97.3\] (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Overall and specific survival

Toxicity {#Sec14}
--------

Acute toxicity was previously reported \[[@CR9]\]. No G ≥ 3 late toxicity was observed. Sixteen late toxicities occurred (G1: 14 events \[87.5%\]). G1 breast fibrosis and hypopigmentation of puncture site were the most frequent late side effects. The rates of excellent and good cosmetic outcome were 76.4 and 25.6% respectively. A breast asymmetry was noticed in 2 pts (4%) (Table [2](#Tab2){ref-type="table"}). Table 2Late toxicity outcomeLate ToxicityNumber of events%Grade 1 Breast fibrosis531.3 Puncture site hypopig.531.3 Telangectasia212.5 Epithelitis16.3 Other16.3 Total1487.5Grade 2 Breast fibrosis212.5 Total number of events16100Cosmetic outcomeNumber of estimations% Excellent3976.4 Good1225.6*Puncture site hypopig* Puncture site hypopigmentation

Discussion {#Sec15}
==========

This update short report confirms the excellent outcome of our cohort \[[@CR9]\]. After a median follow-up of 64 months, no local relapse occurred while SS rate was 100% in this elderly cohort. The challenge in this population is alleviating the treatment, preserving oncological outcome and functional status. A vAPBI based on a post-operative single fraction appeared as an attractive technical option. Indeed, it drastically reduces the number of transportations, alleviates the treatment related constraints (mainly for elderly patients with frequent comorbidities) without compromise regarding local control \[[@CR5]\]. Furthermore, the post-operative irradiation setting permits treating only validated candidates for APBI due to an appropriate definitive pathological report compatible with APBI criteria.

vAPBI also could be considered as a smart alternative to the omission of adjuvant radiation therapy which has been considered for elderly patients. Indeed, in phase III randomized trials which compared surgery + hormonal therapy with or without adjuvant WBI, there was a significant over-risk of local recurrence without breast irradiation \[[@CR14], [@CR15]\]. In our study, there was no local relapse and there was no cancer related death. Due to the deleterious impact of aromatase inhibitors on the quality of life \[[@CR16]\], it is currently discussed to promote adjuvant breast irradiation without hormonal therapy in the elderly with low-risk breast cancer \[[@CR17], [@CR18]\].

Other studies reported encouraging results of vAPBI in patients presenting low-risk breast cancer and confirmed the safety and the efficiency of this new approach (Table [3](#Tab3){ref-type="table"}) \[[@CR6]--[@CR8], [@CR19]--[@CR23]\]. Table 3Very APBI discribed in the litteratureAuthorsYear\# ptsMFU (months)Irradiation techniquesTotal dose (Gy)D/f (Gy)AG3 tox (%)LG3 tox (%)LF (%)RF (%)DM (%)Ex/goodcosmetic resultsSacchini2008183431HDR~IORT~20/1820/187.7--0----aKhan20133011Contura™287 (BID)00--------Wilkinson2012/174574Mammosite™287 (BID)13.3200091Showalter2016286HDR~IORT~12.512.50--------93Latorre20182024HDR~MIB~18180000580Khan201920012HDR~MIB~/Contura™22,57,51.5--1----97Jethwa20197314Balloon2173----------SiFEBI2018/192663HDR~MIB~16167.6000--88Study--4839HDR~MIB~16166.30020100*\# pts.* number of patients, *MFU* Median follow-up, *HDR*~*IORT*~ High-dose rate brachytherapy performed intra-operatively, *MIB* Multicatheter interstitial high-dose rate brachytherapy, *Dose/f* Dose per fraction, *AG3tox* Acute Grade 3 toxicity, *LG3tox* Late Grade 3 toxicity, *LF* Local failure, *RF* Regional failure, *DM* Distant metastasis, *Ex/gd cosmetic results* Percentages of excellent and good cosmetic results, *APBI* Accelerated partial breast irradiation^a^Cosmetic results were better with 18 Gy compared to 20 Gy

Conclusion {#Sec16}
==========

We confirmed promising and encouraging clinical outcome of a post-operative single fraction of MIB ABPI in the elderly. This approach leads to consider vAPBI as an attractive alternative to intra-operative radiation therapy while all the patients will be good candidates for APBI in regards to the post-operative pathological report. VAPBI allows to drastically reducing the number of transportations and fatigue for elderly patients.
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